Singaporean medical technology company Aevice Health and the National University Health System have announced a partnership to conduct a clinical trial using the former’s portable breathing monitor.
The AI-powered portable stethoscope AeviceMD detects and simultaneously records chest sounds from a distance. The sounds are then analyzed and translated into heart rate and breathing rate measurements, while showing abnormalities such as wheezing.
WHY IT IS IMPORTANT
NUHS found that one in five children in Singapore has asthma, one of the most common chronic diseases that affects 14% of children worldwide. The condition can be “difficult to manage” if children cannot communicate their symptoms or realize they are experiencing them, resulting in “underdiagnosis, under-treatment, and inadequate control of the disease.”
The health group, through its Center for Innovation in Healthcare, will investigate the use of AeviceMD in detecting wheezing, a major symptom of asthma, in children with breathing difficulties at the National University Hospital. It already recruited participants in September and aims to complete the study by the second quarter of 2022.
Dr. Michael Lim, the study’s lead investigator, said Aevice Health’s breath monitor “has the potential to improve remote patient monitoring and be useful in situations like the current COVID-19 pandemic where patient contact needs to be minimized.
The NUH senior advisor also noted that his “ability to detect abnormal lung sounds can also be useful in homes for early detection of wheezing in children and for immediate attention from caregivers”.
THE BIGGER TREND
Aevice Health is also researching and developing a predictive model for asthma attacks in pediatric patients using a portable continuous monitoring device.
In other news, the company secured over $ 2 million in a Pre-Series A financing round in which Toho Holdings and SEEDS Capital of Enterprise Singapore, among others, participate. The proceeds from the investment event were used to develop its breath monitoring solution and enter Japan. Aevice Health has entered into a strategic partnership with medical device wholesaler Toho Holdings to commercialize AeviceMD in Japan.
ON THE RECORD
“This study will further validate the value of AeviceMD for providers and patients by enabling objective, continuous and remote detection of lung noise anomalies to further bridge the gap between providers and clinicians,” said Adrian Ang, CEO of Aevice Health.
“Using AeviceMD as a novel remote ventilation monitor can provide providers with insights beyond the hospital to better understand factors that lead to an exacerbation and enable more tailored and patient-centric outcomes. We are excited about how the use of AeviceMD can improve the way chronic respiratory diseases [are] treated and understood, “he added.